These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

553 related items for PubMed ID: 22236796

  • 21. Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study.
    Lahdes-Vasama TT, Anttila A, Wahl E, Taskinen S.
    Scand J Urol Nephrol; 2011 Dec; 45(6):397-400. PubMed ID: 21740110
    [Abstract] [Full Text] [Related]

  • 22. Botulinum toxin injections for adults with overactive bladder syndrome.
    Duthie J, Wilson DI, Herbison GP, Wilson D.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD005493. PubMed ID: 17636801
    [Abstract] [Full Text] [Related]

  • 23. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
    Amundsen CL, Komesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF, Vasavada SP, Nguyen JN, Wilson TS, Harvie HS, Wallace D, Pelvic Floor Disorders Network.
    Eur Urol; 2018 Jul 18; 74(1):66-73. PubMed ID: 29482936
    [Abstract] [Full Text] [Related]

  • 24. Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
    Prescrire Int; 2013 Jan 18; 22(134):12-3. PubMed ID: 23367677
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A.
    Eur Urol; 2015 Mar 18; 67(3):577-88. PubMed ID: 24612659
    [Abstract] [Full Text] [Related]

  • 27. Predictors of Poor Response and Adverse Events Following Botulinum Toxin-A for Refractory Idiopathic Overactive Bladder.
    Abrar M, Stroman L, Malde S, Solomon E, Sahai A.
    Urology; 2020 Jan 18; 135():32-37. PubMed ID: 31626856
    [Abstract] [Full Text] [Related]

  • 28. Botulinum toxin injections for adults with overactive bladder syndrome.
    Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D.
    Cochrane Database Syst Rev; 2011 Dec 07; (12):CD005493. PubMed ID: 22161392
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population.
    Onem K, Bayrak O, Demirtas A, Coskun B, Dincer M, Kocak I, Onur R, Turkish Urology Academy, Incontinence/Neurourology Study Group.
    Neurourol Urodyn; 2018 Jan 07; 37(1):263-268. PubMed ID: 28407394
    [Abstract] [Full Text] [Related]

  • 30. Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial.
    Chuang YC, Kaufmann JH, Chancellor DD, Chancellor MB, Kuo HC.
    J Urol; 2014 Dec 07; 192(6):1743-9. PubMed ID: 25046622
    [Abstract] [Full Text] [Related]

  • 31. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
    Al Edwan GM, Mansi HH, Atta ONM, Shaath MM, Al Adwan R, Mahafza W, Afram KM, Ababneh O, Al Adwan D, Muheilan MM.
    J Pediatr Surg; 2019 Mar 07; 54(3):595-599. PubMed ID: 29887168
    [Abstract] [Full Text] [Related]

  • 32. The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial.
    Dowson C, Sahai A, Watkins J, Dasgupta P, Khan MS.
    Int J Clin Pract; 2011 Jun 07; 65(6):698-704. PubMed ID: 21564444
    [Abstract] [Full Text] [Related]

  • 33. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia.
    Chughtai B, Dunphy C, Lee R, Lee D, Sheth S, Marks L, Kaplan SA, Te AE.
    Can J Urol; 2014 Apr 07; 21(2):7217-21. PubMed ID: 24775575
    [Abstract] [Full Text] [Related]

  • 34. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
    Hsiao SM, Lin HH, Kuo HC.
    PLoS One; 2016 Apr 07; 11(1):e0147137. PubMed ID: 26824901
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
    Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C.
    Neurourol Urodyn; 2013 Nov 07; 32(8):1109-15. PubMed ID: 23389824
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
    Denys P, Del Popolo G, Amarenco G, Karsenty G, Le Berre P, Padrazzi B, Picaut P, Dysport Study Group.
    Neurourol Urodyn; 2017 Feb 07; 36(2):457-462. PubMed ID: 26756554
    [Abstract] [Full Text] [Related]

  • 38. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Giannantoni A, Mearini E, Del Zingaro M, Porena M.
    Eur Urol; 2009 Mar 07; 55(3):705-11. PubMed ID: 18814955
    [Abstract] [Full Text] [Related]

  • 39. Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial.
    Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, Schaffer J, Wei J, Chai T, Janz N, Spino C, Meikle S, Pelvic Floor Disorders Network.
    Contemp Clin Trials; 2012 Jan 07; 33(1):184-96. PubMed ID: 22008247
    [Abstract] [Full Text] [Related]

  • 40. [INJECTION OF BOTULINUM TOXIN TYPE A IN THE BLADDER DETRUSOR AND SUBMUCOSA IN PATIENTS WITH OVERACTIVE BLADDER WITHOUT DETRUSOR OVERACTIVITY].
    Krivoborodov GG, Tur EI, Efremov NS.
    Urologiia; 2015 Jan 07; (2):31-4. PubMed ID: 26237802
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.